Point Biopharma Global Stock Retained Earnings
POINT Biopharma Global fundamentals help investors to digest information that contributes to POINT Biopharma's financial success or failures. It also enables traders to predict the movement of POINT Stock. The fundamental analysis module provides a way to measure POINT Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to POINT Biopharma stock.
POINT |
POINT Biopharma Global Company Retained Earnings Analysis
POINT Biopharma's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current POINT Biopharma Retained Earnings | 39.01 M |
Most of POINT Biopharma's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, POINT Biopharma Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
CompetitionBased on the latest financial disclosure, POINT Biopharma Global has a Retained Earnings of 39.01 M. This is 95.81% lower than that of the Biotechnology sector and 59.74% lower than that of the Health Care industry. The retained earnings for all United States stocks is 99.58% higher than that of the company.
POINT Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses POINT Biopharma's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of POINT Biopharma could also be used in its relative valuation, which is a method of valuing POINT Biopharma by comparing valuation metrics of similar companies.POINT Biopharma is currently under evaluation in retained earnings category among its peers.
POINT Fundamentals
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X | |||
| Price To Sales | 5.45 X | |||
| Revenue | 226.58 M | |||
| EBITDA | 127.32 M | |||
| Net Income | 98.29 M | |||
| Cash And Equivalents | 199.43 M | |||
| Cash Per Share | 2.21 X | |||
| Total Debt | 3.56 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 10.90 X | |||
| Book Value Per Share | 4.01 X | |||
| Cash Flow From Operations | 183.52 M | |||
| Short Ratio | 0.98 X | |||
| Earnings Per Share | 1.10 X | |||
| Target Price | 12.5 | |||
| Number Of Employees | 129 | |||
| Beta | -0.003 | |||
| Market Capitalization | 1.33 B | |||
| Total Asset | 578.32 M | |||
| Retained Earnings | 39.01 M | |||
| Working Capital | 451.08 M | |||
| Net Asset | 578.32 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |